1. Home
  2. UHS vs KYMR Comparison

UHS vs KYMR Comparison

Compare UHS & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Universal Health Services Inc.

UHS

Universal Health Services Inc.

HOLD

Current Price

$179.08

Market Cap

10.2B

Sector

Health Care

ML Signal

HOLD

Logo Kymera Therapeutics Inc.

KYMR

Kymera Therapeutics Inc.

HOLD

Current Price

$114.57

Market Cap

10.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UHS
KYMR
Founded
1978
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Hospital/Nursing Management
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.2B
10.6B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
UHS
KYMR
Price
$179.08
$114.57
Analyst Decision
Buy
Strong Buy
Analyst Count
11
26
Target Price
★ $216.36
$107.72
AVG Volume (30 Days)
★ 669.1K
608.0K
Earning Date
04-27-2026
04-30-2026
Dividend Yield
★ 0.48%
N/A
EPS Growth
★ 37.34
N/A
EPS
★ 11.63
N/A
Revenue
★ $17,364,829,000.00
$39,211,000.00
Revenue This Year
$7.67
$10.61
Revenue Next Year
$4.99
$8.17
P/E Ratio
$15.22
★ N/A
Revenue Growth
★ 9.71
N/A
52 Week Low
$140.08
$54.09
52 Week High
$246.33
$130.05

Technical Indicators

Market Signals
Indicator
UHS
KYMR
Relative Strength Index (RSI) 56.60 44.32
Support Level $163.44 $110.64
Resistance Level $186.91 $120.37
Average True Range (ATR) 6.06 4.97
MACD 0.03 -0.51
Stochastic Oscillator 61.91 22.86

Price Performance

Historical Comparison
UHS
KYMR

About UHS Universal Health Services Inc.

Universal Health Services Inc offers healthcare services through its behavioral health centers, acute care hospitals, and related outpatient facilities. As of late 2025, the company operated 346 inpatient behavioral health centers, 29 acute care hospitals, and many supportive outpatient facilities. Its operations are concentrated in the U.S, particularly in Nevada (21% of 2025 operating profits), Texas (19%), and California (13%), although it does have some exposure to the UK behavioral health market (6% of 2025 sales) too. While its acute care services account for over 55% of revenue, the behavioral health centers sport higher margins and account for over 55% of pretax profits.

About KYMR Kymera Therapeutics Inc.

Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.

Share on Social Networks: